- Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum.
- In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care.
Vancouver, Canada – April 1, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, is pleased to announce a feature by RheumNow, a leading resource for rheumatologists, exploring the evolving role of 14-3-3eta in rheumatoid arthritis (RA). The Therapeutic Update includes expert commentary from Dr. Walter Maksymowych, who shares clinical insights on how 14-3-3eta supports the diagnosis, prognosis, and monitoring of rheumatoid arthritis (RA).
The featured article and podcast explore how 14-3-3eta helps address critical gaps in the RA care continuum. Beyond aiding early detection—including in seronegative RA—14-3-3eta serves as a modifiable prognostic marker, offering critical insights into treatment response and disease progression. This helps clinicians make more timely, personalized treatment decisions, ultimately improving patient outcomes.
Read the full update on RheumNow: Biomarkers in RA: The role of biomarkers in the full continuum of patient care
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3eta protein, available as JOINTstat® in Canada and Great Britain, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada, expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]